![]() We created an experimental model of alkylation-based chemotherapy using. One atom that is particularly susceptible to alkylation is the. Researchers said their findings "confirms that adjuvant cisplatin-based chemotherapy is of. Dietary Methionine Restriction Plus Temozolomide for. The dietician will give you written instructions and make a food plan based. This diet and chemotherapy. Possible Interactions Between Dietary Antioxidants and Chemotherapy. Possible Interactions Between Dietary Antioxidants. They are a normal part of the human diet. ![]() Paring down treatment for Hodgkin lymphoma may reduce the risk of long-term side effects. Minimizing without hurting cure rates is the challenge. The Truth About Chemotherapy. Alkylating agents are drugs that prevent DNA. Alkylating agents were one of the earliest classes of drugs used to treat cancer, beginning in the 1940’s. The biggest weakness of most cancer cells is that they. Alkylation Based Chemotherapy Diet RecipePlatinum, anthracycline, and alkylating agent- based chemotherapy for ovarian carcinosarcoma. Italian Ministry of Health. ![]() TY - JOURT1 - Platinum, anthracycline, and alkylating agent- based chemotherapy for ovarian carcinosarcoma. AU - Signorelli,Mauro. ![]() ![]() AU - Chiappa,Valentina. AU - Minig,Lucas. AU - Fruscio,Robert. AU - Perego,Patrizia. AU - Caspani,Giovanna. AU - Battistello,Marco. AU - Colombo,Nicoletta. ![]() PY - 2. 00. 9/8. Y1 - 2. N2 - Background: Ovarian carcinosarcoma (OCS) is a rare malignancy associated with a poor prognosis. Platinum, anthracyclines, and alkylating agents are the most effective antiblastic drugs for treatment of gynecologic epithelial and stromal tumors. The aim of this study was to determine response rate and overall survival (OS) of patients with OCS who were treated with a combination of these 3 drugs. Methods: Forty- one women with OCS whowere referred to the Department of Gynecologic Oncology of San Gerardo Hospital in Monza and European Institute of Oncology in Milan, between January 1. December 2. 00. 6, and treated with a combination regimen of cisplatin, adriamycin, and cyclophosphamide or a combination regimen containing of cisplatin, epirubicin, and ifosfamide plus granulocyte colony- stimulating factor were considered for this study. Results: Four women had OCS stage I; 7, stage II; 2. III; and 7, stage IV. Heterologous, homologous, and mixed stromal components were described in 1. Thirteen women were treated with a combination of cisplatin, adriamycin, and cyclophosphamide and 2. Two women did not complete their treatment because of the rapid progression of their disease and severe toxicity. Among 2. 2 women considered evaluable for response, 1. Overall progression- free survival was 1. Y9. 6 months) and 1. IYII and IIIYIV, respectively (P = 0. Median OS was 2. 0 months (range, 1. Y1. 23 months), not reached in stage IYII, and 1. IIIYIV (P = 0. 0. No significant difference between homologous and heterologous sarcomatous components was observed (P = 0. OS was noticed for stage IIICYIV with optimal debulking surgery (n = 9), compared with suboptimal cytored ction (n = 1. P = 0. 1. 4). Conclusion: The combination of anthracycline, alkylating agent, and cisplatin showed a good response rate but also a high toxicity. The prognosis of OCS remains poor. Optimal cytoreductionmay improve survival, but newanticancer drugs or more effective regimens are awaited. Platinum, anthracyclines, and alkylating agents are the most effective antiblastic drugs for treatment of gynecologic epithelial and stromal tumors. The aim of this study was to determine response rate and overall survival (OS) of patients with OCS who were treated with a combination of these 3 drugs. Methods: Forty- one women with OCS whowere referred to the Department of Gynecologic Oncology of San Gerardo Hospital in Monza and European Institute of Oncology in Milan, between January 1. December 2. 00. 6, and treated with a combination regimen of cisplatin, adriamycin, and cyclophosphamide or a combination regimen containing of cisplatin, epirubicin, and ifosfamide plus granulocyte colony- stimulating factor were considered for this study. Results: Four women had OCS stage I; 7, stage II; 2. III; and 7, stage IV. Heterologous, homologous, and mixed stromal components were described in 1. Thirteen women were treated with a combination of cisplatin, adriamycin, and cyclophosphamide and 2. Two women did not complete their treatment because of the rapid progression of their disease and severe toxicity. Among 2. 2 women considered evaluable for response, 1. Overall progression- free survival was 1. Y9. 6 months) and 1. IYII and IIIYIV, respectively (P = 0. Median OS was 2. 0 months (range, 1. Y1. 23 months), not reached in stage IYII, and 1. IIIYIV (P = 0. 0. No significant difference between homologous and heterologous sarcomatous components was observed (P = 0. OS was noticed for stage IIICYIV with optimal debulking surgery (n = 9), compared with suboptimal cytored ction (n = 1. P = 0. 1. 4). Conclusion: The combination of anthracycline, alkylating agent, and cisplatin showed a good response rate but also a high toxicity. The prognosis of OCS remains poor. Optimal cytoreductionmay improve survival, but newanticancer drugs or more effective regimens are awaited.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
July 2017
Categories |